Mark Chin
Director/Board Member at DISC MEDICINE, INC.
Net worth: - $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
John Quisel | M | 53 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 4 years |
Ron Hunt | M | 59 |
Iterum Therapeutics US Holding Ltd.
Iterum Therapeutics US Holding Ltd. Financial ConglomeratesFinance Iterum Therapeutics US Holding Ltd. operates as a clinical-stage pharmaceutical company. The company was founded in 2018 and is headquartered in Chicago, IL.
Iterum Therapeutics International Ltd.
Iterum Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland. | 7 years |
Robert Lyne | M | 41 | 7 years | |
Julia Eastland | F | 59 | 6 years | |
Gordon Hamilton | M | - |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | - |
Joanne Bryce | F | 57 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 7 years |
Patrick Heron | M | 53 |
Iterum Therapeutics International Ltd.
Iterum Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland.
Iterum Therapeutics US Holding Ltd.
Iterum Therapeutics US Holding Ltd. Financial ConglomeratesFinance Iterum Therapeutics US Holding Ltd. operates as a clinical-stage pharmaceutical company. The company was founded in 2018 and is headquartered in Chicago, IL. | 7 years |
Georges Gemayel | M | 64 | 3 years | |
Brent Ahrens | M | 61 |
Iterum Therapeutics International Ltd.
Iterum Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland. | 9 years |
James Healy | M | 59 |
Iterum Therapeutics US Holding Ltd.
Iterum Therapeutics US Holding Ltd. Financial ConglomeratesFinance Iterum Therapeutics US Holding Ltd. operates as a clinical-stage pharmaceutical company. The company was founded in 2018 and is headquartered in Chicago, IL.
Iterum Therapeutics International Ltd.
Iterum Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland. | 6 years |
Mohammed Malik | M | 56 |
Iterum Therapeutics International Ltd.
Iterum Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland. | 5 years |
Kevin Bitterman | M | 47 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 7 years |
Mona Ashiya | M | 55 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 3 years |
William White | M | 51 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 4 years |
Donald Nicholson | M | 67 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 5 years |
William Savage | M | 50 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 4 years |
Liam Ratcliffe | M | 60 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 5 years |
Min Wang | M | - |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
Jan Pinkas | M | - | 3 years | |
Bradley Backes | M | - |
Optikira LLC
Optikira LLC BiotechnologyHealth Technology Optikira LLC engages in the development of novel therapeutics to prevent cell death diseases such as retinitis pigmentosa, diabetes, and amyotrophic lateral sclerosis. The company was founded by Bradley Backes, Dustin Maly, Scott Oakes, and Feroz Papa in 2015 and is headquartered in Cleveland, OH. | 10 years |
Steve Allen | M | - |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | - |
Judith Matthews | F | 54 |
Iterum Therapeutics US Holding Ltd.
Iterum Therapeutics US Holding Ltd. Financial ConglomeratesFinance Iterum Therapeutics US Holding Ltd. operates as a clinical-stage pharmaceutical company. The company was founded in 2018 and is headquartered in Chicago, IL.
Iterum Therapeutics International Ltd.
Iterum Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland. | - |
Feroz Papa | M | - |
Optikira LLC
Optikira LLC BiotechnologyHealth Technology Optikira LLC engages in the development of novel therapeutics to prevent cell death diseases such as retinitis pigmentosa, diabetes, and amyotrophic lateral sclerosis. The company was founded by Bradley Backes, Dustin Maly, Scott Oakes, and Feroz Papa in 2015 and is headquartered in Cleveland, OH. | 10 years |
Freda Lewis-Hall | M | 69 | 3 years | |
Sailaja Puttagunta | M | 55 | 6 years | |
Pamela Connealy | F | 63 | 3 years | |
Frank Lanza | M | 62 | 5 years | |
Louise Barrett | F | - |
Iterum Therapeutics US Holding Ltd.
Iterum Therapeutics US Holding Ltd. Financial ConglomeratesFinance Iterum Therapeutics US Holding Ltd. operates as a clinical-stage pharmaceutical company. The company was founded in 2018 and is headquartered in Chicago, IL.
Iterum Therapeutics International Ltd.
Iterum Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland. | - |
Beth Hecht | F | 60 | 3 years | |
Jay Backstrom | M | 69 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 3 years |
Thomas Civik | M | 55 | 3 years | |
Jean Franchi | F | 57 | - | |
Corey Fishman | M | 59 |
Iterum Therapeutics International Ltd.
Iterum Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland.
Iterum Therapeutics US Holding Ltd.
Iterum Therapeutics US Holding Ltd. Financial ConglomeratesFinance Iterum Therapeutics US Holding Ltd. operates as a clinical-stage pharmaceutical company. The company was founded in 2018 and is headquartered in Chicago, IL. | - |
Yen Wen Yu | M | - | 4 years | |
Kush Parmar | M | 42 |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
David Kelly | M | 63 |
Iterum Therapeutics International Ltd.
Iterum Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland.
Iterum Therapeutics US Holding Ltd.
Iterum Therapeutics US Holding Ltd. Financial ConglomeratesFinance Iterum Therapeutics US Holding Ltd. operates as a clinical-stage pharmaceutical company. The company was founded in 2018 and is headquartered in Chicago, IL. | - |
Darren Cline | M | 59 | 3 years | |
Chatan Charan | M | - | 2 years | |
Rahul Khara | M | - | - | |
Thibault Roulon | M | - |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | - |
Tim Xu | M | - |
Optikira LLC
Optikira LLC BiotechnologyHealth Technology Optikira LLC engages in the development of novel therapeutics to prevent cell death diseases such as retinitis pigmentosa, diabetes, and amyotrophic lateral sclerosis. The company was founded by Bradley Backes, Dustin Maly, Scott Oakes, and Feroz Papa in 2015 and is headquartered in Cleveland, OH. | - |
Wendy Chang | F | - | 2 years | |
Rachael Lester | F | - | 7 years | |
Jitendra Wadhane | M | 44 | 3 years | |
Srikanth Venkatraman | M | - |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 7 years |
Kouki Harasaki | M | - |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
Nihal Sinha | M | - |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
Banmeet Anand | M | - | 2 years | |
Lachlan Mackinnon | M | - |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | - |
Steven Aronin | M | - | 7 years | |
Uyanga Chuluunbaatar | M | - |
Avoro Ventures LLC
Avoro Ventures LLC Investment ManagersFinance Avoro Ventures LLC (Avoro Ventures) is a venture capital subsidiary of Avoro Capital Advisor LLC founded in 2020. The firm is headquartered in New York. | 2 years |
Robert Black | M | 65 |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | 12 years |
Ronald M. Lindsay | M | 76 |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | - |
Timothy J. Pelura | M | - |
Optikira LLC
Optikira LLC BiotechnologyHealth Technology Optikira LLC engages in the development of novel therapeutics to prevent cell death diseases such as retinitis pigmentosa, diabetes, and amyotrophic lateral sclerosis. The company was founded by Bradley Backes, Dustin Maly, Scott Oakes, and Feroz Papa in 2015 and is headquartered in Cleveland, OH. | 6 years |
James Bucher | M | 59 | 1 years | |
Michael Dunne | M | 64 |
Iterum Therapeutics International Ltd.
Iterum Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland. | - |
Baiju R. Shah | M | 52 |
Optikira LLC
Optikira LLC BiotechnologyHealth Technology Optikira LLC engages in the development of novel therapeutics to prevent cell death diseases such as retinitis pigmentosa, diabetes, and amyotrophic lateral sclerosis. The company was founded by Bradley Backes, Dustin Maly, Scott Oakes, and Feroz Papa in 2015 and is headquartered in Cleveland, OH. | - |
Paula Soteropoulos | F | 56 |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | 4 years |
Brenton Ahrens | M | - |
Iterum Therapeutics US Holding Ltd.
Iterum Therapeutics US Holding Ltd. Financial ConglomeratesFinance Iterum Therapeutics US Holding Ltd. operates as a clinical-stage pharmaceutical company. The company was founded in 2018 and is headquartered in Chicago, IL. | - |
John Berriman | M | 76 |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | 9 years |
Luke Walker | M | - | 2 years | |
Albert Seymour | M | 56 |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
Eric M. Snyder | M | - |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | - |
Ted Torphy | M | - |
Optikira LLC
Optikira LLC BiotechnologyHealth Technology Optikira LLC engages in the development of novel therapeutics to prevent cell death diseases such as retinitis pigmentosa, diabetes, and amyotrophic lateral sclerosis. The company was founded by Bradley Backes, Dustin Maly, Scott Oakes, and Feroz Papa in 2015 and is headquartered in Cleveland, OH. | - |
Holger Wesche | M | 56 | 6 years | |
Pamela Stephenson | F | 56 | - | |
Haibo Wang | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Brian MacDonald | M | - |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | - |
Joseph Anderson | M | 65 |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | 5 years |
Jonathan Peacock | M | 66 |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | 5 years |
James McArthur | M | 62 | 4 years | |
David Steinberg | M | 52 | 3 years | |
Luke Evnin | M | 60 | 5 years | |
Gerald McMahon | M | 69 | 5 years | |
Michael Gray | M | 53 | - | |
Patrick Baeuerle | M | 66 | 5 years | |
Georgia Erbez | F | 57 | 4 years | |
Scott Myers | M | 57 | 6 years | |
Marcus Karia | M | - | - | |
Laura Williams | M | 61 | - | |
Edward Conner | M | 51 | 3 years | |
Joanne Viney | M | 58 | 3 years | |
John Ettinger | M | - |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | 3 years |
Andrew Robbins | M | 48 | 4 years | |
John Matthew Patrick Hutton | M | 69 | - | |
James Rawlingson | M | 57 | 3 years | |
Naseem Amin | M | 62 | 2 years | |
Joseph Bailes | M | 67 | 4 years | |
David C. U'Prichard | M | 75 | - | |
Alan Colowick | M | 61 | 2 years | |
Mette Agger | F | 59 | 5 years | |
Lauren Silvernail | F | 65 | 2 years | |
Meghan Fitzgerald | M | 53 | 2 years | |
Jonathan Drachman | M | 62 | 6 years | |
Paul Edick | M | 67 | 4 years | |
David Bonita | M | 48 | - | |
Christopher Evans | M | 67 |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | 9 years |
John Banham | M | 83 | - | |
Franz Humer | M | 76 | 3 years | |
Timothy Blomfield | M | - |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | 7 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 75 | 75.00% |
Ireland | 14 | 14.00% |
United Kingdom | 12 | 12.00% |
France | 6 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mark Chin
- Personal Network